Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase.
Journal: Journal of medicinal chemistry
Published: May 30, 2020
Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A.
Journal: Molecular cancer therapeutics
Published: October 10, 2019
Cytomegalovirus Infection among Infants in Neonatal Intensive Care Units, California, 2005 to 2016.
Journal: American journal of perinatology
Published: March 22, 2019
Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi® and Epclusa®.
Journal: Bioorganic & medicinal chemistry letters
Published: November 24, 2018
Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi®.
Journal: Bioorganic & medicinal chemistry letters
Published: October 08, 2018
Assessing the Workplace Culture and Learning Climate in the Inpatient Operating Room Suite at an Academic Medical Center.
Journal: Journal of surgical education
Published: July 16, 2018
Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition.
Journal: Journal of medicinal chemistry
Published: March 13, 2018
Showing 1-8 of 8
Last Updated: 09/26/2026